Što bi promjena vodstva FDA mogla značiti za odluke o razvoju peptida 2026

What actually changed at FDA in 2026, and what is still only a nomination?

Peptide Information Supplier Peptides Co A nomination hearing does not itself change peptide approval, compounding or quality requirements. Assess issued actions separately: srpanj 2026 peptide guidance revisions and the October pending policy review have their own status and scope. Leadership discussion should not replace that product-specific review.

The advisory-committee question is where the FDA advisory committee peptide review intersects the leadership transition. Senators pressed Overton to commit to strengthening FDA advisory committees and sought assurances the committees would keep their role, against a backdrop of roughly 50 scientific and technical advisory committees and panels that are convening far less often (reporting on the confirmation hearing, C&EN, 2026). Odvojeno, reporting describes an overhaul of the PCAC roster ahead of the July meeting, with members having peptide-industry ties added (reported roster changes before the vote, Pharmaphorum, 2026). That account is single-source and gives no member count, so treat it as reported rather than established.

What did the peptide advisory panel vote on, and what does that vote legally do?

srpanj 2026 votes recommend, and nothing more. FDA’s own description of how advisory committees work states that recommendations are “just that, advice, and do not bind the agency to any decision,” with the final regulatory decision resting with the agency (FDA’s own description of how advisory committees work, trenutni 2026). The committee’s charter language in the Federal Register frames its job as making appropriate recommendations to the Commissioner on compounding under sections 503A and 503B (the committee’s charter language in the Federal Register, 2015).

<lik klasa="blog-ljestvica" stil="maksimalna širina:640px;margina:1.5rem auto;veličina fonta:12px;linija-visina:1.3;boja:naslijediti"> <svg viewBox="0 0 560 380" stil="maksimalna širina: 100%; visina: auto; obitelj-fontova: 'Između', sustav-ui, sans-serif; boja: #1e293b; --chart-muted: #64748b;" uloga="img" aria-labelledby="pcac-peptide-votes-july-2026-title pcac-peptide-votes-july-2026-desc"> <stil> /* Renderer stavlja grafikon u iframe čija je pozadina elementa crna, a iframe je različitog oblika od grafikona, pa su se trake poštanskog sandučića pokazivale kao crni okviri oko njega (proizvod 09-22). Dokument unutar iframea je prema zadanim postavkama proziran; slikanje ovdje pokriva pozadinu elementa, a kada je grafikon umetnut umjesto toga, ovo ne odgovara ničemu. Držite kutne zagrade izvan ovog bloka: element stila unutar SVG-a analizira se kao strani sadržaj, tako da jedna zalutala zagrada odbacuje svako pravilo u sebi. */ html, tijelo { pozadina: #ffffff; margina: 0; } @mediji (preferira-smanjeno-kretanje: smanjiti) { * { animacija: nijedan !važno; prijelaz: nijedan !važno; } } </stil> <pravougaonik x="0" y="0" širina="560" visina="380" rx="8" popuniti="#ffffff" /> <naslov id="pcac-peptide-votes-july-2026-title">PCAC peptide votes, July 2026</titula> <desc id="pcac-peptide-votes-july-2026-desc">PCAC peptide votes, srpanj, kako je ucrtano iz citiranog izvora. PCAC peptide votes, srpanj 2026. grupirani podaci o trakama: BPC-157: Da 8, Ne 6, Abstain 1; KPV: Da 8, Ne 6, Abstain 1; TB-500: Da 8, Ne 6, Abstain 1; c-RIJEČI: Da 7, Ne 5, Abstain 2; Ne slušaj: Da 8, Ne 5, Abstain 1; Epitalon: Da 7, Ne 4, Abstain 1; Emideltide/DSIP: Da 6, Ne 7, Abstain 1.Source: McDermott Will & Šmirgl, PCAC recap 2026-07-28.</desc> <tekst x="280.0" y="29" tekst-sidro="sredini" veličina-fonta="18" težina-fonta="800" popuniti="trenutnaBoja">PCAC peptide votes, July 2026</tekst> <line x1="72" y1="277.0" x2="492" y2="277.0" stroke="trenutnaBoja" opacity="0.08" /> <line x1="72" y1="230.8" x2="492" y2="230.8" stroke="trenutnaBoja" opacity="0.08" /> <line x1="72" y1="184.5" x2="492" y2="184.5" stroke="trenutnaBoja" opacity="0.08" /> <line x1="72" y1="138.2" x2="492" y2="138.2" stroke="trenutnaBoja" opacity="0.08" /> <line x1="72" y1="92.0" x2="492" y2="92.0" stroke="trenutnaBoja" opacity="0.08" /> <tekst x="66" y="281.0" tekst-sidro="end" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.7">0</tekst> <tekst x="66" y="234.8" tekst-sidro="end" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.7">2.5</tekst> <tekst x="66" y="188.5" tekst-sidro="end" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.7">5</tekst> <tekst x="66" y="142.2" tekst-sidro="end" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.7">7.5</tekst> <tekst x="66" y="96.0" tekst-sidro="end" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.7">10</tekst> <pravougaonik x="72.0" y="62" širina="10" visina="10" popuniti="#f97316" /> <tekst x="87.0" y="71" veličina-fonta="11" popuniti="trenutnaBoja">Da</tekst> <pravougaonik x="127.6" y="62" širina="10" visina="10" popuniti="#38bdf8" /> <tekst x="142.6" y="71" veličina-fonta="11" popuniti="trenutnaBoja">Ne</tekst> <pravougaonik x="177.0" y="62" širina="10" visina="10" popuniti="#a78bfa" /> <tekst x="192.0" y="71" veličina-fonta="11" popuniti="trenutnaBoja">Abstain</tekst> <pravougaonik x="79.0" y="129.0" širina="13.3" visina="148.0" popuniti="#f97316" /> <tekst x="85.7" y="125.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">8</tekst> <pravougaonik x="94.3" y="166.0" širina="13.3" visina="111.0" popuniti="#38bdf8" /> <tekst x="101.0" y="162.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">6</tekst> <pravougaonik x="109.7" y="258.5" širina="13.3" visina="18.5" popuniti="#a78bfa" /> <tekst x="116.3" y="254.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">1</tekst> <tekst x="102.0" y="295.0" tekst-sidro="sredini" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.8"><tspan x="102.0" dy="0">BPC-157</tspan></tekst> <pravougaonik x="139.0" y="129.0" širina="13.3" visina="148.0" popuniti="#f97316" /> <tekst x="145.7" y="125.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">8</tekst> <pravougaonik x="154.3" y="166.0" širina="13.3" visina="111.0" popuniti="#38bdf8" /> <tekst x="161.0" y="162.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">6</tekst> <pravougaonik x="169.7" y="258.5" širina="13.3" visina="18.5" popuniti="#a78bfa" /> <tekst x="176.3" y="254.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">1</tekst> <tekst x="162.0" y="295.0" tekst-sidro="sredini" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.8"><tspan x="162.0" dy="0">KPV</tspan></tekst> <pravougaonik x="199.0" y="129.0" širina="13.3" visina="148.0" popuniti="#f97316" /> <tekst x="205.7" y="125.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">8</tekst> <pravougaonik x="214.3" y="166.0" širina="13.3" visina="111.0" popuniti="#38bdf8" /> <tekst x="221.0" y="162.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">6</tekst> <pravougaonik x="229.7" y="258.5" širina="13.3" visina="18.5" popuniti="#a78bfa" /> <tekst x="236.3" y="254.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">1</tekst> <tekst x="222.0" y="295.0" tekst-sidro="sredini" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.8"><tspan x="222.0" dy="0">TB-500</tspan></tekst> <pravougaonik x="259.0" y="147.5" širina="13.3" visina="129.5" popuniti="#f97316" /> <tekst x="265.7" y="143.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">7</tekst> <pravougaonik x="274.3" y="184.5" širina="13.3" visina="92.5" popuniti="#38bdf8" /> <tekst x="281.0" y="180.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">5</tekst> <pravougaonik x="289.7" y="240.0" širina="13.3" visina="37.0" popuniti="#a78bfa" /> <tekst x="296.3" y="236.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">2</tekst> <tekst x="282.0" y="295.0" tekst-sidro="sredini" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.8"><tspan x="282.0" dy="0">c-RIJEČI</tspan></tekst> <pravougaonik x="319.0" y="129.0" širina="13.3" visina="148.0" popuniti="#f97316" /> <tekst x="325.7" y="125.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">8</tekst> <pravougaonik x="334.3" y="184.5" širina="13.3" visina="92.5" popuniti="#38bdf8" /> <tekst x="341.0" y="180.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">5</tekst> <pravougaonik x="349.7" y="258.5" širina="13.3" visina="18.5" popuniti="#a78bfa" /> <tekst x="356.3" y="254.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">1</tekst> <tekst x="342.0" y="295.0" tekst-sidro="sredini" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.8"><tspan x="342.0" dy="0">Ne slušaj</tspan></tekst> <pravougaonik x="379.0" y="147.5" širina="13.3" visina="129.5" popuniti="#f97316" /> <tekst x="385.7" y="143.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">7</tekst> <pravougaonik x="394.3" y="203.0" širina="13.3" visina="74.0" popuniti="#38bdf8" /> <tekst x="401.0" y="199.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">4</tekst> <pravougaonik x="409.7" y="258.5" širina="13.3" visina="18.5" popuniti="#a78bfa" /> <tekst x="416.3" y="254.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">1</tekst> <tekst x="402.0" y="295.0" tekst-sidro="sredini" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.8"><tspan x="402.0" dy="0">Epitalon</tspan></tekst> <pravougaonik x="439.0" y="166.0" širina="13.3" visina="111.0" popuniti="#f97316" /> <tekst x="445.7" y="162.0" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">6</tekst> <pravougaonik x="454.3" y="147.5" širina="13.3" visina="129.5" popuniti="#38bdf8" /> <tekst x="461.0" y="143.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">7</tekst> <pravougaonik x="469.7" y="258.5" širina="13.3" visina="18.5" popuniti="#a78bfa" /> <tekst x="476.3" y="254.5" tekst-sidro="sredini" veličina-fonta="9" popuniti="trenutnaBoja">1</tekst> <tekst x="462.0" y="295.0" tekst-sidro="sredini" veličina-fonta="10" popuniti="trenutnaBoja" opacity="0.8"><tspan x="462.0" dy="0">Emideltide/DSIP</tspan></tekst> <tekst x="280.0" y="366" tekst-sidro="sredini" veličina-fonta="10" popuniti="naše(--chart-muted, trenutnaBoja)">Izvor: McDermott Will & Šmirgl, PCAC recap (2026-07-28)</tekst> </svg> </lik>

The procedural record is precise. The April 2026 Federal Register notice opening the docket set the meeting for 23 i 24 srpanj 2026, established docket FDA-2025-N-6895, and closed comments on 22 srpanj 2026, with comments received by 9 July provided to the committee (the April 2026 Federal Register notice opening the docket, 91 FR 20465). A firm-by-firm readout of the votes reports the tallies below; no official minutes were located, so they are labelled as reported from the public meeting (a firm-by-firm readout of the votes, McDermott Will & Šmirgl, 2026).

The 8–6–1 split is the modal outcome, and DSIP is the only substance the committee voted against. A favourable vote places nothing on the 503A bulks list and authorises no compounding. FDA’s explanation of its interim categories is equally clear that removal from Category 2 only lifts a do-not-compound posture; it is not a listing, i Kategorija 1 is a non-enforcement posture rather than an approval (FDA’s explanation of its interim categories, trenutni 2026).

How would a peptide actually get reclassified, and how long does that take?

There is no statutory deadline, and the precedent runs in years, not months. As of mid-October 2026 no proposed or final rule existed; FDA must decide whether to accept the recommendations, publish a proposed rule, take comments, then issue a final rule, and the closest precedent is a 2016 proposed rule on 10 bulk substances finalised in 2019 (a late-October status review, Nizozemska & Vitez, 2026).

The 2019 proposed rule shows the shape of the step. It proposed to place 5 substances on the list and not to place 26 others, set comments due 4 prosinac 2019, and proposed that any final rule take effect 30 days after publication (the 2019 proposed rule, 84 FR 46688). Siječanj 2025 interim-policy notice adds the holding pattern: existing Category 1 substances stay within the policy until FDA promulgates a final rule determining whether they will be placed on the 503A bulks list (the January 2025 interim-policy notice, 2025).

Upozorenje: No statutory deadline governs this sequence. The 503A and 503B lists also run on different legal tests, so progress on one says nothing about the other.

The 503B track illustrates the divergence. FDA’s 503B notice on the GLP-1 peptides proposed not to include semaglutide, tirzepatide and liraglutide, requires at least 60 days for comment, and applies a clinical-need finding that excludes shortage, convenience and cost (FDA’s 503B notice on the GLP-1 peptides, 91 FR 23431). The 503B bulks-list notice mechanism is a comment notice followed by a designating notice, and shortage status operates as a separate pathway rather than a clinical-need argument (the 503B bulks-list notice, 2026).

Five stages, u redu, each with no guaranteed next step: Peptide Manufacturer Manufacturer

1. PCAC vote (advisory only)

2. FDA decision on whether to accept the recommendation

3. Proposed rule published

4. Comment period (90 days in the 2019 precedent; najmanje 60 days on the 503B track)

5. Final rule, djelotvoran 30 days after publication in that precedent

What does decision-quality analytical data mean for a peptide, field by field?

A peptide characterization package is decision-quality when every number is tied to a named method, a defined column and a stated detection wavelength, and when identity is established orthogonally rather than inferred from purity. I Q2(R2), usvojen na Step 4 in November 2023, enumerates the performance characteristics a method must demonstrate and renames “validation characteristic” as “performance characteristic” (I Q2(R2), usvojen na Step 4 in November 2023, ja, 2023).

A lot package should carry the method identifier, the chromatogram and not only the purity figure, an orthogonal identity result, counterion and net-peptide content, sadržaj vode, endotoxin by USP <85> LAL where the material is injectable, i sterilnost prema USP <71>, which is distinct from USP <61> microbial enumeration. No USP monograph was identified for BPC-157, KPV, TB-500, c-RIJEČI, Epitalon, Semax or emideltide, so the USP chapters apply as testing frameworks rather than peptide-specific specifications.

Ključ za van: Purity reported as relative area percent is never identity, sadržaj, stability or assay suitability on its own.

A supplier package that reads “RP-HPLC, C18 column, water/acetonitrile gradient, UV detekcija na 220 nm, purity 99.2%” with the chromatogram attached is auditable. A line reading “HPLC purity: 99%” is not, because it cannot be reproduced or challenged.

How do research material, compounded preparation and approved drug differ in evidence and documentation?

Approved medicines, lawful compounded preparations and research materials differ in regulatory basis and evidence. Odjeljak 216.23(d) concerns substances listed in that provision; it does not establish that every compounded medicine lacks safety or effectiveness evidence.

Labelling does not settle intent. An August 2026 warning letter found that research-use-only and not-for-human-consumption labelling did not establish non-drug intent where website claims plus the sale of bacteriostatic water as a reconstitution solvent showed intended human use, and it named semaglutide, retatrutide, SS-31, PT-141 and tesamorelin (an August 2026 pismo upozorenja, FDA, Ref. 735127). Removal from Category 2 lifts a do-not-compound posture only, and a favourable vote changes none of the three columns above.

Which signals should a program lead watch, and what decision does each trigger?

Each signal below maps to one decision, so you are not re-litigating the same question every month. The nomination track is the first: a committee vote or floor vote on Overton is the trigger to re-read the agency’s stated priorities, and until then the acting commissioner remains the operative fact (the Senate HELP Committee’s September 2026 nomination hearing, 2026).

The interim access policy submitted to OMB on 14 listopad 2026 had not been issued, and the likely near-term route is enforcement discretion, which approves no product and could be withdrawn without rulemaking; a second PCAC meeting is expected before end-February 2027 za GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF (a late-October status review, Nizozemska & Vitez, 2026).

The decision rule that holds regardless of how the review settles is this: treat characterization data as the only variable you control, and build the lot package to method level now. If you need to benchmark your current supplier documentation against that standard, requesting a lot-specific data package and walking it through the field list above with a technical specialist is one way to do it.

Često postavljana pitanja

Does the July 2026 advisory committee vote make these peptides legal to compound?

Ne. FDA states that advisory committee recommendations do not bind the agency, and a favourable vote places nothing on the 503A bulks list (FDA’s own description of how advisory committees work, trenutni 2026). Removal from Category 2 lifts a do-not-compound posture only.

How long until a peptide could actually be listed?

No statutory deadline exists. The closest precedent is a 2016 proposed rule finalised in 2019, i 2019 proposed rule itself carried a comment period closing December 4, 2019 and a proposed effective date set out in section VI (the 2019 proposed rule, 84 FR 46688).

Is a certificate of analysis the same as an approval?

Ne. A certificate of analysis is a snapshot of one lot against defined methods, and it does not represent approval, licenciranje, safety or efficacy, or authorisation for human or animal use. Ask for the method and the chromatogram behind each figure.

Does research-use-only labelling protect a supplier?

Not by itself. An August 2026 warning letter found that research-use-only labelling did not establish non-drug intent where website claims and the sale of bacteriostatic water showed intended human use (an August 2026 pismo upozorenja, FDA, Ref. 735127).

Zaključak

What you can act on is the data. Build the lot package to method level, insist on the chromatogram and the orthogonal identity result, and hold the distinction between purity and identity firmly enough that a favourable headline cannot blur it. Then watch the five signals above and let each one move a decision rather than a mood.

The next step is small and immediate: take one current lot package and check it against the field list in the characterization section. Whatever the review does next, that package will still be the part of your program you can defend.

O izdavaču. MOL Changes is a peptide research and development organization that offers custom sequence design, synthesis and modification services, and production of peptides for laboratory research and commercial applications. It has a commercial interest in peptide supply, so weigh its perspective accordingly. The guidance above does not depend on its products.

Jinling Liu

Proces R&D i tehničar proizvod Temeljna stručnost: Proširivanje procesa, zelena kemija, poboljšanje prinosa, Sukladnost proizvodnje s GMP-om.

O autoru Najnovije objave

Profil: Jinling Liu specijalizirao se za prevođenje procesa peptidnih lijekova iz laboratorijskih razmjera (razina miligrama) na proizvodnju komercijalnih razmjera (razina kilograma). Predana je značajnom smanjenju troškova proizvodnje peptida i smanjenju onečišćenja okoliša optimizacijom uvjeta cijepanja, poboljšanje omjera kondenzacijskih reagensa, i uvođenje tehnologije sinteze kontinuiranog protoka. Vodila je optimizaciju više peptidnih projekata, uspješno postizanje niske cijene, masovna proizvodnja visoke čistoće u mjerilu od 100 kilograma.

• Što nas istraživanje far-crvenih fotoreceptora uči o dizajniranju boljih peptidnih sondi 2026年10月25日
• Što bi promjena vodstva FDA mogla značiti za odluke o razvoju peptida 2026 2026年10月25日
• Digitalni blizanci u proizvodnji peptida: Šest područja za procjenu za podršku odlučivanju 2026年10月25日
• Precizno označeni peptidi za nanobiosenzore: Zahtjevi za dizajn i karakterizaciju 2026年10月24日
• Live-Neuron Protein Imaging: Lekcije za validaciju sonde obilježenog peptida 2026年10月24日

Činjenica provjerena & Uredničke smjernice

Naš postupak provjere činjenica

Prioritet nam je točnost i integritet u našem sadržaju. Evo kako održavamo visoke standarde:

1. Stručni pregled: Sve članke recenziraju stručnjaci za predmet.
2. Provjera valjanosti izvora: Informacije su potkrijepljene vjerodostojnim, ažurni izvori.
3. Transparentnost: Jasno navodimo reference i otkrivamo potencijalne sukobe.

Pregledao: Stručnjaci za predmet

Naš odbor za reviziju

Naš sadržaj pažljivo pregledavaju iskusni stručnjaci kako bi osigurali točnost i relevantnost.

• Kvalificirani stručnjaci: Svaki članak ocjenjuju stručnjaci sa specifičnim znanjem o tom području.
• Ažurni uvidi: Uključujemo najnovija istraživanja, trendovi, i standardima.
• Posvećenost kvaliteti: Recenzenti osiguravaju jasnoću, ispravnost, i potpunost.

Potražite oznaku koju su pregledali stručnjaci da biste pročitali sadržaj kojem možete vjerovati.